Telcagepant: A New Therapeutic Option for Acute Migraine? | Zendy

E. Anne MacGregor | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Telcagepant: A New Therapeutic Option for Acute Migraine?

Author(s) -

E. Anne MacGregor

Publication year - 2011

Publication title -

clinical medicine insights therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.205

H-Index - 9

ISSN - 1179-559X

DOI - 10.4137/cmt.s7477

Subject(s) - triptans , migraine , tolerability , medicine , calcitonin gene related peptide , drug class , migraine treatment , drug , pharmacology , adverse effect , neuropeptide , receptor

Telcagepant (MK0974) is one of several calcitonin-gene-related peptide antagonists in development as a potential treatment for acute migraine attacks and is the first orally available drug in this class. Preclinical and clinical data are reviewed, which support the efficacy and tolerability of telcagepant for the treatment of migraine, particularly for patients unable to tolerate, or who have cardiovascular contraindications to, triptans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research